Description
Global Epilepsy Devices Market Research Report—Forecast till 2027
Market Overview
Global Epilepsy Devices Market anticipated record a significant CAGR of 6.56% during the review period of 2020 to 2027. Epilepsy is an incurable disease caused because of neurological complications and necessarily prevalent and repeatedly rising old age population. As per the Mayo Clinic (US), epilepsy is a central nervous system (neurological) disease in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. The global market growth is attributed to the increasing prevalence of epilepsy amongst the geriatric population, rising cases of brain injuries owing to road accidents, a large patient pool suffering from neurological disorders, and growing research funding in epilepsy.
The global Epilepsy devices market is expected to witness a healthy market owing to the highest market value of USD 551.2 Million in 2019. The expansion of the global epilepsy devices market is driven by a large patient pool suffering from neurological disorders. As per the WHO, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. The inherent and expanding demand for novel therapies to solve epilepsy-related problems is boosting the manufacturers to develop innovative products.
Market Segmentation
Global Epilepsy Devices Market has been categorized into Product Type, Technology, Seizure Detection and Prediction Devices, and End-Use.
In terms of product type, the global epilepsy devices market is classified into wearable devices, conventional devices, and implantable devices. The wearable devices segment is further classified into watches, bracelets, camera devices, mattress devices, anti-suffocation pillows, and others. Based on technology type, the global epilepsy devices market has been divided into vagus nerve stimulation, responsive neurostimulation, deep brain stimulation, and accelerometry.
By seizure detection and prediction devices, the global market has been segmented into electroencephalogram, intracranial EEG, surface electromyography, electrodermal activity, electrocardiography, video detection systems, implanted advisory systems, and others. Based on the end-user segment, the global epilepsy devices market has been segregated into hospitals & clinics, neurology centers, home care settings, and others.
Regional Analysis
Geographically, the Global Epilepsy Devices Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global epilepsy devices market due to a large number of companies operating in the region, government regulations, and the increasing healthcare expenditure in the region. The region accounted for a considerable market share of 40.3% in the global epilepsy devices market.
Europe is expected to register the second largest market of the global epilepsy devices market during the forecast period, due to the availability of reimbursement, rising geriatric population prone to epilepsy, and technological advancements in therapeutic devices. Additionally, the presence of highly developed healthcare infrastructure and the research funds from governmental organizations is expected to have a positive impact on the European epilepsy devices market.
Asia-Pacific is expected to register the fastest growing market owing to the increasing population, rising number of patients suffering from epilepsy, the growing awareness about the available treatment options, and strategic decisions by key players operating in the region. The market for epilepsy devices is increasing in the Middle East and Africa (MEA) owing to rising product launches in the region.
Major Players
The Key Players in the Global Epilepsy Devices Market are Boston Scientific Corporation, Medpage Ltd. (Easylink UK), Cerbomed GmbH (TVNS Technologies GmbH), Liva Nova (Cyberonics), Compumedics, Nihon Kohden, MC10, Empatica, Inc, Medtronic Plc, Neuropace, Inc, and Natus Medical Incorporated.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 17
1.2 MARKET ATTRACTIVENESS ANALYSIS 18
1.2.1 GLOBAL EPILEPSY DEVICES MARKET, BY PRODUCT TYPE 18
1.2.1.1 GLOBAL EPILEPSY DEVICES MARKET, BY WEARABLE DEVICES 19
1.2.2 GLOBAL EPILEPSY DEVICES MARKET, BY TECHNOLOGY 20
1.2.3 GLOBAL EPILEPSY DEVICES MARKET, BY SEIZURE DETECTION AND PREDICTION DEVICES 21
1.2.4 GLOBAL EPILEPSY DEVICES MARKET, BY END USE 22
1.2.5 GLOBAL EPILEPSY DEVICES MARKET, BY REGION 23
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 24
2.2 RESEARCH OBJECTIVE 24
2.3 MARKET STRUCTURE 25
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 26
3.2 PRIMARY RESEARCH 27
3.3 SECONDARY RESEARCH 28
3.4 MARKET SIZE ESTIMATION 28
3.5 FORECAST MODEL 30
3.6 LIST OF ASSUMPTIONS & LIMITATIONS 31
4 MARKET DYNAMICS
4.1 INTRODUCTION 32
4.2 DRIVERS 33
4.2.1 RISING PREVALENCE OF EPILEPSY AMONGST THE GERIATRIC POPULATION 33
4.2.2 INCREASING CASES OF BRAIN INJURIES DUE TO ROAD ACCIDENTS 33
4.2.3 RISING NEUROLOGICAL DISORDERS 33
4.2.4 INCREASING RESEARCH FUNDING IN EPILEPSY 34
4.2.5 DRIVERS IMPACT ANALYSIS 34
4.3 RESTRAINTS 35
4.3.1 LOSS OF PATENT PROTECTION FOR BRANDED DRUGS 35
4.3.2 HIGH COSTS ASSOCIATED WITH THE TREATMENT OF EPILEPSY 35
4.3.3 RESTRAINTS IMPACT ANALYSIS 35
4.4 OPPORTUNITIES 36
4.4.1 ENTERING DEVELOPING ECONOMIES 36
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN 37
5.1.1 RESEARCH & DEVELOPMENT AND DESIGNING 37
5.1.2 MANUFACTURING 37
5.1.3 DISTRIBUTION & SALES 37
5.1.4 POST-SALES SERVICES 38
5.2 PORTER’S FIVE FORCES MODEL 38
5.2.1 THREAT OF NEW ENTRANTS 38
5.2.2 BARGAINING POWER OF SUPPLIERS 39
5.2.3 THREAT OF SUBSTITUTES 39
5.2.4 BARGAINING POWER OF BUYERS 39
5.2.5 INTENSITY OF RIVALRY 39
5.3 IMPACT OF COVID-19 ON THE GLOBAL EPILEPSY DEVICES MARKET 39
5.3.1 OVERVIEW 39
5.3.2 IMPACT ON SUPPLY CHAIN 40
5.3.3 IMPACT ON PRODUCTION/MANUFACTURERS 40
5.3.4 IMPACT ON REGIONS 40
5.3.5 IMPACT ON DEMAND 40
6 GLOBAL EPILEPSY DEVICES MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION 41
6.2 WEARABLE DEVICES 42
6.2.1 WATCHES 43
6.2.2 BRACELETS 43
6.2.3 CAMERA DEVICES 43
6.2.4 MATTRESS DEVICES 44
6.2.5 ANTI-SUFFOCATION PILLOWS 44
6.2.6 OTHERS 44
6.3 CONVENTIONAL DEVICES 45
6.4 IMPLANTABLE DEVICES 45
7 GLOBAL EPILEPSY DEVICES MARKET BY TECHNOLOGY
7.1 OVERVIEW 46
7.2 VAGUS NERVE STIMULATION (VNS) 47
7.3 RESPONSIVE NEUROSTIMULATION 47
7.4 DEEP BRAIN STIMULATION 48
7.5 ACCELEROMETRY 48
8 GLOBAL EPILEPSY DEVICES MARKET, BY SEIZURE DETECTION AND
PREDICTION DEVICES
8.1 OVERVIEW 49
8.2 ELECTROENCEPHALOGRAM (EEG) 50
8.3 INTRACRANIAL EEG 51
8.4 SURFACE ELECTROMYOGRAPHY (SEMG) 51
8.5 ELECTRODERMAL ACTIVITY (EDA) 51
8.6 ELECTROCARDIOGRAPHY (EKG) 52
8.7 VIDEO DETECTION SYSTEMS 52
8.8 IMPLANTED ADVISORY SYSTEMS 53
8.9 OTHERS 53
9 GLOBAL EPILEPSY DEVICES MARKET, BY END USE
9.1 OVERVIEW 54
9.2 HOSPITALS & CLINICS 55
9.3 NEUROLOGY CENTERS 55
9.4 HOME CARE SETTINGS 56
9.5 OTHERS 56
10 GLOBAL EPILEPSY DEVICES MARKET, BY REGION
10.1 INTRODUCTION 57
10.2 AMERICAS 58
10.2.1 NORTH AMERICA 61
10.2.1.1 US 64
10.2.1.2 CANADA 66
10.2.2 LATIN AMERICA 68
10.3 EUROPE 70
10.3.1 WESTERN EUROPE 73
10.3.1.1 GERMANY 76
10.3.1.2 FRANCE 78
10.3.1.3 UK 80
10.3.1.4 ITALY 82
10.3.1.5 SPAIN 84
10.3.1.6 REST OF WESTERN EUROPE 86
10.3.2 EASTERN EUROPE 88
10.4 ASIA-PACIFIC 90
10.4.1 CHINA 93
10.4.2 INDIA 95
10.4.3 JAPAN 97
10.4.4 AUSTRALIA 99
10.4.5 SOUTH KOREA 101
10.4.6 REST OF ASIA-PACIFIC 103
10.5 MIDDLE EAST & AFRICA 105
10.5.1 MIDDLE EAST 108
10.5.2 AFRICA 110
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVE OVERVIEW 112
11.2 COMPETITOR DASHBOARD 112
11.3 MARKET SHARE ANALYSIS 113
11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL EPILEPSY DEVICES MARKET 114
11.5 COMPETITIVE BENCHMARKING 115
11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPILEPSY DEVICES MARKET 116
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 117
11.7.1 PRODUCT DEVELOPMENTS/LAUNCHES 117
11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES 118
11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 118
11.8.1 SALES & OPERATING INCOME 118
11.8.2 R&D EXPENDITURE 119
12 COMPANY PROFILES
12.1 BOSTON SCIENTIFIC CORPORATION 120
12.1.1 COMPANY OVERVIEW 120
12.1.2 FINANCIAL OVERVIEW 121
12.1.3 PRODUCTS/SERVICES OFFERED 122
12.1.4 KEY DEVELOPMENTS 122
12.1.5 SWOT ANALYSIS 123
12.1.6 KEY STRATEGIES 123
12.2 MEDPAGE LTD. (EASYLINK UK) 124
12.2.1 COMPANY OVERVIEW 124
12.2.2 FINANCIAL OVERVIEW 124
12.2.3 PRODUCTS/SERVICES OFFERED 124
12.2.4 KEY DEVELOPMENTS 125
12.2.5 SWOT ANALYSIS 125
12.2.6 KEY STRATEGIES 125
12.3 CERBOMED GMBH (TVNS TECHNOLOGIES GMBH) 126
12.3.1 COMPANY OVERVIEW 126
12.3.2 FINANCIAL OVERVIEW 126
12.3.3 PRODUCTS/SERVICES OFFERED 126
12.3.4 KEY DEVELOPMENTS 126
12.3.5 SWOT ANALYSIS 127
12.3.6 KEY STRATEGIES 127
12.4 LIVA NOVA (CYBERONICS) 128
12.4.1 COMPANY OVERVIEW 128
12.4.2 FINANCIAL OVERVIEW 129
12.4.3 PRODUCTS/SERVICES OFFERED 129
12.4.4 KEY DEVELOPMENTS 130
12.4.5 SWOT ANALYSIS 130
12.4.6 KEY STRATEGIES 130
12.5 COMPUMEDICS 131
12.5.1 COMPANY OVERVIEW 131
12.5.2 FINANCIAL OVERVIEW 131
12.5.3 PRODUCTS/SERVICES OFFERED 132
12.5.4 KEY DEVELOPMENTS 132
12.5.5 SWOT ANALYSIS 133
12.5.6 KEY STRATEGIES 133
12.6 NIHON KOHDEN 134
12.6.1 COMPANY OVERVIEW 134
12.6.2 FINANCIAL OVERVIEW 135
12.6.3 PRODUCTS/SERVICES OFFERED 136
12.6.4 KEY DEVELOPMENTS 136
12.6.5 SWOT ANALYSIS 137
12.6.6 KEY STRATEGIES 137
12.7 MC10 138
12.7.1 COMPANY OVERVIEW 138
12.7.2 FINANCIAL OVERVIEW 138
12.7.3 PRODUCTS/SERVICES OFFERED 138
12.7.4 KEY DEVELOPMENTS 138
12.7.5 SWOT ANALYSIS 139
12.7.6 KEY STRATEGIES 139
12.8 EMPATICA, INC. 140
12.8.1 COMPANY OVERVIEW 140
12.8.2 FINANCIAL OVERVIEW 140
12.8.3 PRODUCTS/SERVICES OFFERED 140
12.8.4 KEY DEVELOPMENTS 140
12.8.5 SWOT ANALYSIS 141
12.8.6 KEY STRATEGIES 141
12.9 MEDTRONIC PLC 142
12.9.1 COMPANY OVERVIEW 142
12.9.2 FINANCIAL OVERVIEW 143
12.9.3 PRODUCTS/SERVICES OFFERED 143
12.9.4 KEY DEVELOPMENTS 144
12.9.5 SWOT ANALYSIS 144
12.9.6 KEY STRATEGIES 144
12.10 NEUROPACE, INC. 145
12.10.1 COMPANY OVERVIEW 145
12.10.2 FINANCIAL OVERVIEW 145
12.10.3 PRODUCTS/SERVICES OFFERED 145
12.10.4 KEY DEVELOPMENTS 145
12.10.5 SWOT ANALYSIS 146
12.10.6 KEY STRATEGIES 146
12.11 NATUS MEDICAL INCORPORATED 147
12.11.1 COMPANY OVERVIEW 147
12.11.2 FINANCIAL OVERVIEW 148
12.11.3 PRODUCTS/SERVICES OFFERED 149
12.11.4 KEY DEVELOPMENTS 149
12.11.5 SWOT ANALYSIS 150
12.11.6 KEY STRATEGIES 150
13 APPENDIX
13.1 REFERENCES 151″
